Tagged with innovation,

Switzerland The Chief Scientific Officer and President of Glenmark Pharmaceuticals Swiss R&D Center elaborates on Glenmark’s endeavor to venture up the pharmaceutical value chain and discusses the company’s R&D strategy. Furthermore, he highlights the significance of strategic partnerships in today’s pharmaceutical R&D efforts. You have spent 23 years working in large…

Taiwan Jui-Lin Chen, CEO of MiCareo, provides insights into the development of MiSelect, Micareo’s pioneering platform for the analysis of Circulating Tumor Cells (CTC) and other rare cells, which proudly stands as the best product available to physicians for cancer prognosis as well as the perfect companion diagnostic for drug development…

Switzerland The most innovative country in the world must constantly launch new initiatives to attract R&D activities if that lead is to be maintained, and Switzerland Innovation is doing just that – by showcasing the opportunities that the Swiss Innovation Park holds for innovative companies around the world. Switzerland Innovation was…

Taiwan Chen Min-Che, founder and managing director of Asclepiumm, provides insights into the main milestones reached and the new partnership opportunities considered by this exciting biotech company, whose Antibody Switch-on Cytotoxicity (ASC) technology platform could contribute to bringing onto the global market a novel class of “smart cell-penetrating proteins” in multiple…

Switzerland Switzerland has been long-established as one of the world’s most innovative countries and boasts a thriving ecosystem of startup biotechs. However, a slow and complex funding cycle means that an increasing number of Swiss biotechs are looking towards the US for funding; a trend that risks destabilising and weakening the…

Switzerland Recognized as one of the ten most innovative companies in the world, Hamilton has a regional HQ, strategic R&D and manufacturing operations tucked high away in the scenic Swiss Alps. Andreas Wieland, CEO of Hamilton’s Swiss businesses, discusses the company’s approach to innovation and the factors that have helped Switzerland…

Taiwan Mike Exton, Managing Director at Novartis Taiwan, describes the affiliate’s plans to increase collaboration with the government in order to provide Taiwanese patients with a greater access to innovative, life-changing products, while highlighting Novartis’ world-class innovation in many critical therapeutic areas, such as heart failure, as well as the skilled…

Greece Amgen’s mission is clear cut: ‘To Serve Patients’, which is evident in the level of innovation that they bring as the world’s leading biotech company. Complementary to this message is one that GM of Amgen Greece Arvela Matti, strongly wants to reverberate across the Greek pharmaceutical landscape: innovation is an…

Mexico M.S. Nagendra, Director General at Zydus Pharmaceuticals Mexico, explains the company’s unique business model, combining both branded generics and highly innovative medicines, while showcasing the strategic relevance of the Mexican affiliate within the global strategy of the company. Could you introduce yourself to our international readers as well as the…

Greece  Astellas Greece & Cyprus MD, Harry Nardis, emphasizes the importance of integrity, compliance and innovation to the Astellas business model, key priorities, navigating the Greek pharmaceutical landscape while maintaining a high-quality reputation, and retaining the company’s vision of being at the forefront of healthcare change. Having assumed the leadership position…

Switzerland Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics touched upon by KPMG Switzerland’s head of life sciences Martin Rohrbach. On February 12th the Swiss people rejected the Tax…

Taiwan Tse Wen Chang, internationally recognized as one of the greatest contributors to the biotech field, and founder, CEO, and president of Immunwork, provides insights into the company’s ground-breaking T-E™ pharmaceuticals, which combine both targeting (T) and effector (E) moieties to form a new class of innovative drugs displaying significantly enhanced…